Background: Interleukin-16 (IL-16) is a cytokine that induces selective migration of CD4+ cells and participates in inflammatory diseases including allergic rhinitis. Histamine and prostaglandin D2 are important chemical mediators of allergic inflammation, and antiallergic drugs are commonly used for the treatment of allergic rhinitis. It remains unknown whether treatment with the drugs affects IL-16. Objective: We evaluated the variability of IL-16 and the effects of the antiallergic drugs fexofenadine (40 mg/kg/day) and ramatroban (30 mg/kg/day) on IL-16 in an OVA-sensitized BALB/c murine experimental allergic rhinitis model. Methods: We measured the expression level of IL-16 protein in the mouse nasal septal mucosa by immunohistochemistry, and the serum level of IL-16 by ELISA. Several other parameters associated with allergic rhinitis (nasal symptoms, OVA-specific IgE, eosinophil and T cell infiltration) were also measured. Results: Local and systemic expressions of IL-16 were significantly increased in OVA-sensitized mice when compared to the nonsensitized group. Fexofenadine and ramatroban significantly inhibited the following OVA-induced allergic features when compared to the nontreated sensitized group: sneezing, nasal rubbing, eosinophil infiltration, IL-16 expressions in nasal tissue, and serum IL-16 level. Serum OVA-specific IgE and local T cell infiltration were reduced, but they did not reach significant values. Conclusions: These results suggest that IL-16 was both systemically and locally upregulated in the murine allergic rhinitis model and that IL-16 changed in parallel to allergic state by treatment with the drugs.

Keywords:
Interleukin-16, Allergic rhinitis, Eosinophils, Nasal mucosa, Ovalbumin-sensitized mouse, Fexofenadine, Ramatoban
1.
Cruikshank W, Center DM: Modulation of lymphocyte migration by human lymphokines. II. Purification of a lymphotactic factor (LCF). J Immunol 1982;128:2569–2574.
2.
Center DM, Kornfeld H, Cruikshank WW: Interleukin 16 and its function as a CD4 ligand. Immunol Today 1996;17:476–481.
3.
Laberge S, Ernst P, Ghaffar O, Cruikshank WW, Kornfeld H, Center DM, Hamid Q: Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma. Am J Respir Cell Mol Biol 1997;17:193–202.
4.
Franz JK, Kolb SA, Hummel KM, Lahrtz F, Neidhart M, Aicher WK, Pap T, Gay RE, Fontana A, Gay S: Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+ T lymphocytes in rheumatoid arthritis. Eur J Immunol 1998;28:2661–2671.
5.
Laberge S, Ghaffar O, Boguniewicz M, Center DM, Leung DY, Hamid Q: Association of increased CD4+ T-cell infiltration with increased IL-16 gene expression in atopic dermatitis. J Allergy Clin Immunol 1998;102:645–650.
6.
Yoshimoto T, Wang CR, Yoneto T, Matsuzawa A, Cruikshank WW, Nariuchi H: Role of IL-16 in delayed-type hypersensitivity reaction. Blood 2000;95:2869–2874.
7.
Cruikshank WW, Kornfeld H, Center DM: Interleukin-16. J Leukoc Biol 2000;67:757–766.
8.
Mathy NL, Bannert N, Norley SG, Kurth R: Cutting edge: CD4 is not required for the functional activity of IL-16. J Immunol 2000;164:4429–4432.
9.
Lynch EL, Little FF, Wilson KC, Center DM, Cruikshank WW: Immunomodulatory cytokines in asthmatic inflammation. Cytokine Growth Factor Rev 2003;14:489–502.
10.
De Bie JJ, Jonker EH, Henricks PA, Hoevenaars J, Little FF, Cruikshank WW, Nijkamp FP, Van Oosterhout AJ: Exogenous interleukin-16 inhibits antigen-induced airway hyper-reactivity, eosinophilia and Th2-type cytokine production in mice. Clin Exp Allergy 2002;32:1651–1658.
11.
El Bassam S, Pinsonneault S, Kornfeld H, Ren F, Menezes J, Laberge S: Interleukin-16 inhibits interleukin-13 production by allergen-stimulated blood mononuclear cells. Immunology 2006;117:89–96.
12.
Laberge S, Durham SR, Ghaffar O, Rak S, Center DM, Jacobson M, Hamid Q: Expression of IL-16 in allergen-induced late-phase nasal responses and relation to topical glucocorticosteroid treatment. J Allergy Clin Immunol 1997;100:569–574.
13.
Karaki M, Dobashi H, Kobayashi R, Tokuda M, Ishida T, Mori N: Expression of interleukin-16 in allergic rhinitis. Int Arch Allergy Immunol 2005;138:67–72.
14.
Hessel EM, Cruikshank WW, Van Ark I, De Bie JJ, Van Esch B, Hofman G, Nijkamp FP, Center DM, Van Oosterhout AJ: Involvement of IL-16 in the induction of airway hyper-responsiveness and up-regulation of IgE in a murine model of allergic asthma. J Immunol 1998;160:2998–3005.
15.
Pullerits T, Linden A, Malmhall C, Lotvall J: Effect of seasonal allergen exposure on mucosal IL-16 and CD4+ cells in patients with allergic rhinitis. Allergy 2001;56:871–877.
16.
Sugimoto Y, Kawamoto E, Chen Z, Kamei C: A new model of allergic rhinitis in rats by topical sensitization and evaluation of H (1)-receptor antagonists. Immunopharmacology 2000;48:1–7.
17.
Saito H, Howie K, Wattie J, Denburg A, Ellis R, Inman MD, Denburg JA: Allergen-induced murine upper airway inflammation: local and systemic changes in murine experimental allergic rhinitis. Immunology 2001;104:226–234.
18.
Watanabe N, Matsuda E, Masuda A, Nariai K, Shibasaki T: The effects of fexofenadine on eosinophilia and systemic anaphylaxis in mice infected with Trichinella spiralis. Int Immunopharmacol 2004;4:367–375.
19.
Kayasuga R, Sugimoto Y, Watanabe T, Kamei C: Participation of chemical mediators other than histamine in nasal allergy signs: a study using mice lacking histamine H(1) receptors. Eur J Pharmacol 2002;449:287–291.
20.
Masuda K, Katoh N, Soga F, Kishimoto S: The role of interleukin-16 in murine contact hypersensitivity. Clin Exp Immunol 2005;140:213–219.
21.
Rasband WS: ImageJ. Bethesda, US National Institutes of Health, 1997–2007. http://rsb.info.nih.gov/ij/.
22.
Lim KG, Wan HC, Bozza PT, Resnick MB, Wong DT, Cruikshank WW, Kornfeld H, Center DM, Weller PF: Human eosinophils elaborate the lymphocyte chemoattractants. IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol 1996;156:2566–2570.
23.
Cruikshank WW, Long A, Tarpy RE, Komfeld H, Carroll MP, Teran L, Holgate ST, Center DM: Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Respir Cell Mol Biol 1995;13:738–747.
24.
Mashikian MV, Tarpy RE, Saukkonen JJ, Lim KG, Fine GD, Cruikshank WW, Center DM: Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. J Allergy Clin Immunol 1998;101:786–792.
25.
Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Reale M, Barbacane RC, Castellani ML, Mortari U, Boucher W, Letourneau R, Theoharides TC: Interleukin-16 network in inflammation and allergy. Allergy Asthma Proc 2002;23:103–108.
26.
Bandeira-Melo C, Sugiyama K, Woods LJ, Phoofolo M, Center DM, Cruikshank WW, Weller PF: IL-16 promotes leukotriene C (4) and IL-4 release from human eosinophils via CD4- and autocrine CCR3-chemokine-mediated signaling. J Immunol 2002;168:4756–4763.
27.
Laberge S, Pinsonneault S, Ernst P, Olivenstein R, Ghaffar O, Center DM, Hamid Q: Phenotype of IL-16-producing cells in bronchial mucosa: evidence for the human eosinophil and mast cell as cellular sources of IL-16 in asthma. Int Arch Allergy Immunol 1999;119:120–125.
28.
de Bie JJ, Henricks PA, Cruikshank WW, Hofman G, Nijkamp FP, van Oosterhout AJ: Effect of interleukin-16-blocking peptide on parameters of allergic asthma in a murine model. Eur J Pharmacol 1999;383:189–196.
29.
Krug N, Cruikshank WW, Tschernig T, Erpenbeck VJ, Balke K, Hohlfeld JM, Center DM, Fabel H: Interleukin 16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 h after allergen challenge in asthma. Am J Respir Crit Care Med 2000;162:105–111.
30.
McFadden C, Morgan R, Rahangdale S, Green D, Yamasaki H, Center D, Cruikshank W: Preferential migration of T regulatory cells induced by IL-16. J Immunol 2007;179:6439–6445.
31.
Gelfand EW, Cui ZH, Takeda K, Kanehiro A, Joetham A: Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 2002;110:85–95.
32.
Xue L, Gyles SL, Wettey WR, Gazi L, Townsend E, Hunter MG, Pettipher R: Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol 2005;175:6531–6536.
33.
Ashenager MS, Grgela T, Aragane Y, Kawada A: Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines. J Investig Allergol Clin Immunol 2007;17:20–26.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.